Table 2.
Changes from baseline in eGFR and albuminuria at follow-up visits by study group
| Variable | Control Group | PTF Group | P Value between Groups |
|---|---|---|---|
| eGFR (ml/min/1.73 m2) | |||
| Mean baseline±SD | 37.6±11.9 | 37.1±12.4 | |
| Least-square mean change±SEM (95% CI) per follow-up period | |||
| 6 mo | −1.7±0.1 (−2.1 to −1.4) | −1.4±0.1 (−1.7 to −1.0) | 0.1 |
| 12 mo | −3.4±0.3 (−4.1 to −2.8) | −1.2±0.3 (−1.9 to -0.6) | <0.001 |
| 18 mo | −5.3±0.3 (−6.1 to −4.5) | −1.7±0.4 (−2.5 to -0.9) | <0.0001 |
| 24 mo | −6.5±0.4 (−7.3 to −5.6) | −2.1±0.4 (−3.0 to -1.2) | <0.0001 |
| UAE | |||
| Median baseline (IQR) (mg/d) | 1000 (600–1800) | 1100 (689–2190) | |
| Least-square mean percentage change per follow-up period±SEM (95% CI) | |||
| 6 mo | 1.4±1.1 (−0.8 to 3.8) | −10.6±1.2 (−13.0 to -8.2) | <0.001 |
| 12 mo | 4.9±2.8 (−0.7 to 10.6) | −13.0±2.9 (−18.8 to −7.2) | <0.0001 |
| 18 mo | 4.9±2.6 (−0.3 to 10.1) | −14.8±2.7 (−20.1 to −9.4) | <0.0001 |
| 24 mo | 5.7±2.7 (−0.3 to 11.1) | −14.9±2.7 (−20.4 to −9.4) | <0.0001 |
| Patients per follow-up period (n) | |||
| 6 mo | 87 | 81 | |
| 12 mo | 85 | 81 | |
| 18 mo | 84 | 79 | |
| 24 mo | 82 | 78 |